1 0 0 antibiotics such as carbapenems (e.g. meropenem) 4 , providing selection pressure for 1 0 1 carbapenem-resistance in gram-negative bacteria. Of great concern has been the 1 0 2 emergence of transmissible carbapenemases in common Enterobacteriaceae. 20 As 1 0 3 part of an international randomised controlled trial of piperacillin-tazobactam (a 1 0 4 potential 'carbapenem-sparing' agent) versus meropenem for the treatment of 3GC-1 0 5 resistant E. coli causing bloodstream infection, 21 we aimed to further characterise 1 0 6 these isolates using whole genome sequencing. To analyse a prospectively collected series of ceftriaxone non-susceptible E. coli 1 1 0 isolated from blood cultures in patients in Australia, New Zealand and Singapore 1 1 1 using whole genome sequencing, in order to characterise antibiotic resistance 1 1 2 genes, sequence types, phylogenetic relationships and plasmid structures. NCT02176122). 21 All E. coli blood culture isolates were included from 70 patients 1 2 2 enrolled in the trial for the first 18 months of recruitment (from February 2014 until 1 2 3
August 2015) from 8 hospital sites in 3 countries. To be eligible for the trial, patients 1 2 4 had to have at least one monomicrobial blood culture growing E. coli, with resistance 1 2 5 to ceftriaxone, ceftazidime or cefotaxime determined by methods used in the local 1 2 6 laboratories (all of which were internationally accredited). All blood culture isolates 1 2 7
were stored at the recruiting site laboratory at -80°C in cryovials containing glycerol 1 2 8 and nutrient broth and later shipped to the co-ordinating laboratory in Queensland, Australia. For the purposes of this study, only the first E. coli isolated from blood All isolates were tested at the co-ordinating laboratory against a standard panel of Filtered reads were mapped to the complete ST131 E. coli reference strain EC958 1 7 7 (Genbank: HG941718.1) using Bowtie as implemented through Nesoni. Non-1 7 8 synonymous mutations were identified using Nesoni nway and manually compared to known mutations in gyrA and parC associated with quinolone resistance. 27, 28 under the (GTR)GAMMA substitution model with Lewis ascertainment bias 1 9 1 correction and a random seed of 456 (100 bootstraps). An ST131 only tree (n=43) 1 9 2 was also created in the same manner using 2,248 recombination-free SNPs and 1 9 3 1000 bootstraps. Phylogenetic trees and associated meta-data were visualised using reflecting the demographics of the largest recruiting sites in Singapore. There were 2 1 4 also a greater proportion of male patients (60%), but this was not statistically 2 1 5 significant (p=0.12). Patients tended to be older (median age 71, IQR 64-81 years, 2 1 6 range 20 to 94 years), although only a small proportion (5.8%) were admitted from 2 1 7 nursing homes. The majority of patients had less severe acute illness (median Pitt illness with high mortality 33 ) and relatively low co-morbidity scores (Charlson score 2 2 0 median 2, IQR 1 to 4, range 0 to 11) and were infrequently admitted to the ICU 2 2 1 (3.1%). Strains demonstrated a variable antibiogram according to ST131 clade (see Table   2 2 4 2), but were frequently resistant to trimethoprim-sulphamethoxazole (46/70, 65.7%) 2 2 5 or fluoroquinolones (52/70, 74.3%). There was universal resistance to ciprofloxacin 2 2 6 in clade C1/C2 ST131, compared with only 50% and 48.2% in clade A and non-2 2 7 ST131 strains respectively (p<0.001). Resistance to aminoglycosides was variable, strains, which were susceptible to ceftriaxone by MIC, were resistant to ceftazidime. Phenotypic resistance to third-generation cephalosporins could not be detected in The presence of aminoglycoside modifying enzymes (AMEs) was common (seen in 3 1 2 76%) and was encountered more frequently in ST131 (86% vs 59%; p=0.011). There were a variety of AME types identified, including those belonging to the aadA, resistance to aminoglycosides, were detected. Acquired quinolone resistance genes (i.e. those not mediated by SNPs in regions 3 2 0 associated with quinolone-resistance) were seen in 11% (8/70). These genes 3 2 1 included qnrS1, qnrB4, qnrB66-like, oqxA or aac(6')Ib-cr (which also mediates 3 2 2 aminoglycoside resistance in addition to low-level quinolone resistance). The 3 2 3 presence of these genes was more commonly seen in non-ST131 than ST131 (22% 3 2 4 vs 5%; p=0.025). EC958 reference strain with respect to mutations in parC and gyrA (supplementary presence of SNPs in parC and gyrA known to be associated with fluoroquinolone 3 3 0 resistance, or the presence of acquired quinolone resistance determinants. resistance was not evident despite the presence of acquired resistance genes (e.g. Sulphonamide resistance genes (sul1, sul2 or sul3) were common, and present in presence of sulphonamide resistance and trimethoprim resistant genes were more 3 4 3 common in ST131 (81% vs 48%, p=0.004, and 74% vs 22%, p<0.001, respectively). Genes mediating resistance to tetracyclines (specifically tet(A) and tet(B)) were seen 3 4 7 in 56% (39/70), but were equally distributed between ST131 and non-ST131. Other collection of E. coli bloodstream isolates. It is also notable that the majority of cases 3 7 0 were of community-onset, with their origin from the urinary tract and in patients over Different beta-lactamase genes were associated with certain E. coli lineages. As has 3 7 8 been described previously, bla CTX-M-15 was largely restricted to the C2 clade amongst recognised as a prominent mediator of resistance in E. coli. [41] [42] [43] [44] [45] In this cohort, p- AmpC (mainly bla CMY-2 ) were not associated with ST131 or any other ST. Previous been CMY-2 41, 44, 46 , with evidence that bla CMY-2 has been mobilised from the in all but two of the E. coli strains carrying bla CMY-2 in our collection, with these 3 9 0 associated with IS1294 and a truncated ISEcp1 (supplementary figure 5). IncF type plasmids have a host range that is limited to Enterobacteriaceae and 3 9 3 contribute to bacterial fitness via antibiotic resistance and virulence determinants. 48 3 9 4
These plasmids have been associated with the rapid emergence and global spread 3 9 5 of bla CTX-M-15 , as well as genes encoding resistance to aminoglycosides and 3 9 6 fluoroquinolones (e.g. aac(6')- Ib-cr, qnr, armA, rmtB) . 48, 49 Similar patterns were also 3 9 7 seen in this study, where the majority of plasmids were of IncF type. There was an trial may preclude those with severe comorbidities or early mortality (prior to 4 1 5 randomisation), it is possible that the E. coli were obtained from patients with less 4 1 6 severe disease, which may be associated with less virulent strains. The MERINO Trial is currently recruiting in an additional 6 countries (Italy, Turkey, 4 1 9
Canada, South Africa, Lebanon and Saudi Arabia) and aims to report in 2018. It is 4 2 0 anticipated that this current work can be augmented by these additional isolates and 4 2 1 provide a global perspective on the molecular epidemiology of contemporary ESBL- to recruit patients and collect bacterial isolates. DLP is the chief investigator for the 4 5 1 MERINO study and conceived the concept for the paper with PH, NLBZ, LR and SB. 
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